Uncertainties in Screening and Prevention of Group B Streptococcus Disease.
expert_opinion · Level V
Where this comes from
- Record sourced from PubMed, PMID 30561556.
- Also identified by DOI 10.1093/cid/ciy1069 and PMC identifier 6669315.
- Licence recorded as CC BY.
- The licence permits redistribution, so the abstract is shown in full and the full text is available from the publisher.
Abstract
In autumn 2016, the UK Department of Health (now Department of Health and Social Care) convened 2 meetings to discuss how to address research evidence gaps in order to minimize the impact of infant group B streptococcus (GBS) disease in the United Kingdom. At that meeting, a number of research priorities were highlighted, including improving the screening for GBS colonization in pregnant women, offering intrapartum antibiotic prophylaxis and point-of-care testing, and understanding the effect of widespread intrapartum antibiotic use on long-term infant health. Further discussions involved investigating the feasibility of a large prospective study of pregnant women and their infants in order to understand the role of antibodies in the protection against GBS disease in infancy following maternal exposure to GBS colonization. Here, we summarize the research uncertainties identified at that meeting.
Medical subject headings
- Infectious Disease Transmission, Vertical
- Pregnancy Complications, Infectious
- Streptococcal Infections
- Streptococcus agalactiae